

# SyrSpend® SF

## Compatibility table

### Legend

- Compatible combination for 30 days
- Compatible combination for 60 days
- Compatible combination for 90 days
- ⊗ Combination not recommended
- ✔ Compatible combination

### Storage temperature

- 🏠 15-25 °C
- ❄️ 2-8 °C

Active pharmaceutical Ingredient (API)	Concentration	SYRSPEND® SF PH4 LIQUID (PRESERVED)		SYRSPEND SF PH4 DRY (UNPRESERVED)	SYRSPEND SF ALKA DRY (UNPRESERVED)		
		Physical and chemical stability	Storage	Physical and chemical stability	Physical and chemical stability	Storage	
Acetaminophen (paracetamol) <sup>16</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Acetazolamide <sup>21</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Allopurinol <sup>16</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Alprazolam <sup>20</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Amiodarone HCl <sup>1</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Amitriptyline HCl <sup>16</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Amlodipine (as besylate) <sup>2</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Atenolol <sup>3</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
	5 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Atropine sulfate <sup>20</sup>	0.1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Baclofen <sup>21</sup>	2 mg/mL	●	❄️	✔	⊗		❄️
	10 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Caffeine <sup>17</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Captopril <sup>4</sup>	0.8 mg/mL	14 days	❄️	✔	⊗		❄️
Carbamazepine <sup>16</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Carvedilol <sup>16</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
	5 mg/mL	●	❄️	✔	⊗		❄️
Celecoxib (capsules) <sup>22</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Chloral hydrate <sup>22</sup>	100 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Chloroquine phosphate <sup>2</sup>	15 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Cholecalciferol (vit. D3) <sup>5</sup>	50,000 IU/mL	●	❄️ / 🏠	✔	⊗		❄️
Ciprofloxacin	50 mg/mL	● / ●	❄️ / 🏠	✔	⊗		❄️
Clomipramine HCl <sup>17</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Clonazepam <sup>3</sup>	0.2 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Clonidine HCl	0.1 mg/mL	7 days	❄️ / 🏠	✔	⊗		❄️
Clopidogrel (as bisulfate, tablets)	5 mg/mL	●	❄️	✔	⊗		❄️
Cloxacillin (capsules)*, <sup>23</sup>	50 mg/mL	5 days	❄️	✔	⊗		❄️
Cyanocobalamin (vit. B12)	0.2 mg/mL	●	🏠	⊗	⊗		⊗
Cyclosporin <sup>22</sup>	100 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Dapsone <sup>2</sup>	2 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Dexamethasone <sup>3</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Diclofenac sodium <sup>3</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Diltiazem HCl <sup>3</sup>	12 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Dipyridamole <sup>21</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗		❄️
Domperidone <sup>16</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗		❄️

## Legend

- Compatible combination for 30 days
- Compatible combination for 60 days
- Compatible combination for 90 days
- ⊗ Combination not recommended
- ✔ Compatible combination

### Storage temperature

- 🏠 15-25 °C
- ❄️ 2-8 °C

Active pharmaceutical Ingredient (API)	Concentration	SYRSPEND® SF PH4 LIQUID (PRESERVED)		SYRSPEND SF PH4 DRY (UNPRESERVED)	SYRSPEND SF ALKA DRY (UNPRESERVED)	Storage
		Physical and chemical stability	Storage	Physical and chemical stability	Physical and chemical stability	
Enalapril maleate <sup>3</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Esomeprazole magnesium <sup>**</sup> , <sup>18</sup>	3 mg/mL	⊗	⊗	⊗	●	❄️
Ethambutol 2 HCl <sup>**</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
	100 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Flecainide acetate (tablets) <sup>22</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Folic acid <sup>17</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Furosemide <sup>1</sup>	10 mg/mL	⊗	⊗	⊗	14	❄️
Gabapentin <sup>6</sup>	50 mg/mL	● / 125 days	❄️ / 🏠	✔	⊗	❄️
Glutamine <sup>20</sup>	250 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Glycopyrrolate (glycopyrronium bromide) <sup>22</sup>	0.5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Griseofulvin	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Haloperidol <sup>5</sup>	0.5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
	2 mg/mL	●	❄️	✔	⊗	❄️
Hydrocortisone <sup>22</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Hydrocortisone hemisuccinate <sup>1</sup>	2 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Hydrocortisone sodium phosphate <sup>1</sup>	2 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Imipramine HCl <sup>5</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Isoniazid <sup>16</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Itraconazole <sup>22</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Ketoconazole <sup>16</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Ketoprofen <sup>3</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Labetalol HCl (tablets)	40 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Lamotrigine <sup>3</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Lansoprazole <sup>18</sup>	2 mg/mL	⊗	⊗	⊗	⊗	⊗
Levodopa and carbidopa <sup>5</sup>	5 / 1.25 mg/mL	● / ●	❄️ / 🏠	✔	⊗	❄️
Levofloxacin <sup>20</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Lisinopril (as dihydrate) <sup>16</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Loperamide HCl <sup>17</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Lorazepam <sup>5</sup>	1 mg/mL	● / ●	❄️ / 🏠	✔	⊗	❄️
Mebeverine HCl <sup>21</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Melatonin <sup>22</sup>	3 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Mercaptopurine	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Methadone HCl	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Methotrexate <sup>17</sup>	2.5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Metoprolol tartrate <sup>20</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Metronidazole benzoate <sup>7</sup>	80 mg/mL	716 days / 366 days	❄️ / 🏠	✔	⊗	❄️
Midazolam (as HCl, injection fluid) <sup>8,19</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Minocycline HCl <sup>5</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️
Nadolol <sup>17</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️

## Legend

- Compatible combination for 30 days
- Compatible combination for 60 days
- Compatible combination for 90 days
- ⊗ Combination not recommended
- ✔ Compatible combination

### Storage temperature

- 🏠 15-25 °C
- ❄️ 2-8 °C

Active pharmaceutical Ingredient (API)	Concentration	SYRSPEND® SF PH4 LIQUID (PRESERVED)		SYRSPEND SF PH4 DRY (UNPRESERVED)	SYRSPEND SF ALKA DRY (UNPRESERVED)		
		Physical and chemical stability	Storage	Physical and chemical stability	Physical and chemical stability	Storage	Storage
Naltrexone HCl <sup>17</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Naproxen <sup>16</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Nifedipine <sup>1</sup>	4 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Nitrendipine (tablets)*, <sup>24</sup>	5 mg/mL	●	🏠	⊗	⊗	⊗	
Nitrofurantoin <sup>20</sup>	2 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Omeprazole**, <sup>9, 18</sup>	2 mg/mL	⊗	⊗	⊗	●	❄️	
	5 mg/mL	⊗	⊗	⊗	●	❄️	
Ondansetron HCl	0.8 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Oseltamivir (as phosphate, capsules) <sup>10, 19</sup>	6 mg/mL	●	❄️	✔	⊗	❄️	
	15 mg/mL	●	❄️	✔	⊗	❄️	
Oxandrolone <sup>20</sup>	3 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Pantoprazole sodium**, <sup>18</sup>	3 mg/mL	⊗	⊗	⊗	●	❄️	
Paracetamol (acetaminophen) <sup>16</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Penicillamine <sup>3</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Pentoxiphylline <sup>17</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Phenobarbital <sup>1</sup>	9 mg/mL	● / 154 days	❄️ / 🏠	✔	⊗	❄️	
	15 mg/mL	●	❄️	✔	⊗	❄️	
Phenytoin <sup>2</sup>	15 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Prednisolone*, <sup>25</sup>	5 mg/mL	●	🏠	⊗	⊗	⊗	
Prednisolone sodium phosphate <sup>1</sup>	1.5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Pregabalin <sup>20</sup>	20 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Propranolol HCl <sup>11, 19</sup>	0.5 mg/mL	●	❄️	✔	⊗	❄️	
	1 mg/mL	146 days	🏠	⊗	⊗	⊗	
	5 mg/mL	●	❄️	✔	⊗	❄️	
Propylthiouracil <sup>21</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Pyrazinamide*, <sup>26</sup>	100 mg/mL	●	🏠	⊗	⊗	⊗	
Pyridoxine HCl (vit. B6) <sup>2</sup>	50 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Quinidine sulfate <sup>21</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Rabeprazole <sup>18</sup>	3 mg/mL	⊗	⊗	⊗	⊗	⊗	
Ranitidine HCl <sup>1</sup>	14 mg/mL	58 days / 36 days	❄️ / 🏠	✔	⊗	❄️	
Riboflavin (vit. B2) <sup>20</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Rifampin (rifampicin) <sup>12</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Sertraline HCl <sup>16</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Sildenafil citrate	2.5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Simvastatin <sup>1</sup>	1 mg/mL	●	❄️	✔	⊗	❄️	
Sotalol HCl (tablets)	5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Spironolactone <sup>1</sup>	2.0 mg/mL	●	❄️	✔	⊗	❄️	
	2.5 mg/mL	●	❄️	✔	⊗	❄️	
	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Spironolactone and hydrochlorothiazide <sup>22</sup>	5/5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	

## Legend

- Compatible combination for 30 days
- Compatible combination for 60 days
- Compatible combination for 90 days
- ⊗ Combination not recommended
- ✔ Compatible combination

### Storage temperature

- 🏠 15-25 °C
- ❄️ 2-8 °C

Active pharmaceutical Ingredient (API)	Concentration	SYRSPEND® SF PH4 LIQUID (PRESERVED)		SYRSPEND SF PH4 DRY (UNPRESERVED)	SYRSPEND SF ALKA DRY (UNPRESERVED)		
		Physical and chemical stability	Storage	Physical and chemical stability	Physical and chemical stability	Storage	Storage
Sulfadiazine <sup>2</sup>	100 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Sulfasalazine <sup>2</sup>	100 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Tacrolimus (as monohydrate) <sup>5</sup>	1 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
	0.5mg/mL	●	❄️	✔	⊗	❄️	
Terbinafine HCl <sup>5</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Tetracycline HCl <sup>2</sup>	25 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Thiamine HCl (vit. B1) <sup>3</sup>	100 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Tiagabine HCl (tablets)	1 mg/mL	● / ●	❄️ / 🏠	✔	⊗	❄️	
Topiramate <sup>21</sup>	5 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Tramadol HCl <sup>5</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Ursodiol (ursodeoxycholic acid) <sup>13</sup>	20 mg/mL	●	❄️	✔	⊗	❄️	
	30 mg/mL	66 days	❄️	✔	⊗	❄️	
Valsartan <sup>5</sup>	4 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	
Vancomycin HCl <sup>14</sup>	25 mg/mL	●	❄️	✔	⊗	❄️	
	50 mg/mL	●	❄️	✔	⊗	❄️	
Verapamil HCl <sup>15</sup>	50 mg/mL	●	❄️	✔	⊗	❄️	
Warfarin sodium (tablets) <sup>*, 27</sup>	1 mg/mL	44 days / 10 days	❄️ / 🏠	✔	⊗	❄️	
Zonisamide <sup>2</sup>	10 mg/mL	●	❄️ / 🏠	✔	⊗	❄️	

\* Study performed by independent scientific working groups without Fagron supervision. For a full list of all references, please be referred to: [www.fagron.com/en/external-study-overview](http://www.fagron.com/en/external-study-overview).

\*\* Use raw pharmaceutical material for the API when compounding.

## Literature references

1. Geiger CM, Sorenson B, Whaley P. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. Int J Pharm Compd. 2015;19:420-7.
2. Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MA, Raposo NR. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J Pharm Biomed Anal 2016;118:105-112.
3. Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D and Thiamine in SyrSpend SF PH4 Oral Suspensions. Int J Pharm Compd. 2016;20:167-174.
4. Geiger CM, Sorenson B, Whaley PA. Stability of Captopril in SyrSpend SF. Int J Pharm Compd. 2013;17:336-338.
5. Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride, valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 2016;71:185-91.
6. Sorenson B, Voudrie MA, Gehrig D. Stability of Gabapentin in SyrSpend SF. Int J Pharm Compd. 2012;16:347-349.
7. Vu NT, Aloumanis V, Ben MJ, Kupiec TC, Patterson EK, Radke J, Erickson MA, Schneider G. Stability of Metronidazole Benzoate in SyrSpend SF One-step Suspension System. Int J Pharm Compd. 2008;12:558-564.
8. Geiger CM, Sorenson B, Whaley PA. Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry. Int J Pharm Compd. 2013;17:344-346.

9. Whaley PA, Voudrie MA, Sorenson B. Stability of Omeprazole in SyrSpend SF Alka (Reconstituted). *Int J Pharm Compd.* 2012;16:164-166.
10. Voudrie MA, Allen B. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup and SyrSpend SF (For Reconstitution). *Int J Pharm Compd.* 2010;14:82-85.
11. Geiger CM, Voudrie MA, Sorensen B. Stability of Propranolol Hydrochloride in SyrSpend SF. *Int J Pharm Compd.* 2012;16:513-515.
12. Sorenson B, Whaley P. Stability of Rifampin in SyrSpend SF. *Int J Pharm Compd.* 2013;17:162-164.
13. Geiger CM, Voudrie MA, Sorenson B. Stability of Ursodiol in SyrSpend SF Cherry Flavored. *Int J Pharm Compd.* 2012;16:510-512.
14. Whaley PA, Voudrie MA. Stability of Vancomycin in SyrSpend SF. *Int J Pharm Compd.* 2012;16:167-169.
15. Voudrie MA, Alexander B, Allen B. Stability of Verapamil Hydrochloride in SyrSpend SF compared to Sorbitol containing syrup and suspending vehicles. *Int J Pharm Compd.* 2011;15:255-258.
16. Polonini HC, Loures S, de Araujo ED, Brandão MAF and Ferreira AO. Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. *Int J Pharm Compd.* 2016;20:426-434.
17. Polonini HC, Silva SL, de Almeida TR, Brandão MAF and Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. *Eur J Hosp Pharm.* 2016 (Published Online First).
18. Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandão MAF and Ferreira AO. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. *Eur J Hosp Pharm* 2016;0:1-7.
19. Dijkers ECF, Nanhekhan V, Thorissen A. Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil. *Int J Pharm Compd.* 2017;21:240-241.
20. Ferreira AO, Polonini HC, Loures da Silva S, Cerqueira de Melo VA, de Andrade L and Brandão MAF. Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabalin, and Riboflavin in SyrSpend SF pH4 Oral Suspensions. *Int J Pharm Compd.* 2017;21:255-263.
21. Polonini HC, Loures da Silva S, Buzinari Aglio NC, Abreu J, Brandão MAF and Ferreira AO. Stability of Acetazolamide, Baclofen, Dipyrindamole, Mebevarine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4. *Int J Pharm Compd.* 2017;21:339-346.
22. Uriel M, Gómez-Rincón C, Marro, D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. *Die Pharmazie.* 2018; 73:196-201.
23. Barbazan C, Le Daré B, Lester MA and Boivin PN. Etude de stabilité d'une suspension buvable de cloxacilline à usage pédiatrique. Poster presentation at 11th Rencontres Convergences Santé Hôpital 2016.
24. Bellay R, Lesourd F, Quilliec C, Gicquel T, Boivin PN and Lester MA. Stabilité d'une suspension buvable de nitrendipine 5 mg/mL. Poster presentation at 11th Rencontres Convergences Santé Hôpital 2016.
25. Bonnaure AC, Bellay R, Rault P, Lester MA and Boivin PN. Stability study of 5 mg/ml pediatric prednisone oral suspension in SyrSpend®. 20th European GERPAC Conference 2017.
26. Boivin P, Geffroy C, Tron C, et al PP-054 Stability study of 100 mg/ml paediatric pyrazinamide oral suspension in syrSpend. *Eur J Hosp Pharm* 2017;24:A225.
27. Guillois G, Fétique L, Perovic I, et al PP-028 Stability study of 1 mg/ml paediatric warfarin oral suspension in syrSpend. *Eur J Hosp Pharm* 2017;24:A214.

Disclaimer: While a great deal of effort has been made to ensure the accuracy of the information contained herein, no claims are made as to the uses, safety, efficacy, or bioavailability of these recommendations. The information cannot be construed as (medical) advice, recommendation, or opinion. Health professionals using this information are advised to do so solely if appropriate in their own professional opinion and judgment. Fagron does not accept and cannot be held responsible or liable in any case for the information contained herein.

